Published in Cancer Weekly, January 29th, 2002
Under the terms of the extension agreement, Rigel will continue to validate targets discovered during the collaboration. Johnson & Johnson Pharmaceutical Research & Development will conduct high-throughput screening and medicinal chemistry to identify small-molecule drugs that modulate validated targets selected for drug discovery.
"Rigel's drug discovery and target validation engine is successfully identifying targets for small-molecule screening at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.